| Names | |
|---|---|
| Preferred IUPAC name | 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole |
| Other names | Losec Prilosec Zegerid Omez Omecip Omezol Mepral AcidFree Omepral |
| Pronunciation | /əˈmɛprəzəʊl/ |
| Identifiers | |
| CAS Number | 73590-58-6 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Omeprazole**: ``` CCCC1=C(N=CN1)COC2=CC=CC=C2S(=O)C3=CC=CC=N3 ``` *(This is the SMILES string representation used for 3D modeling in JSmol)* |
| Beilstein Reference | 87362 |
| ChEBI | CHEBI:7697 |
| ChEMBL | CHEMBL: "CHEMBL1276 |
| ChemSpider | 136101 |
| DrugBank | DB00338 |
| ECHA InfoCard | 100.028.293 |
| EC Number | 3.6.3.10 |
| Gmelin Reference | 82009 |
| KEGG | D08367 |
| MeSH | D000077241 |
| PubChem CID | 4594 |
| RTECS number | ODV30596GW |
| UNII | 6YB4AYL0D3 |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C17H19N3O3S |
| Molar mass | 345.42 g/mol |
| Appearance | White to almost white powder |
| Odor | Odorless |
| Density | 0.7 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 2.23 |
| Vapor pressure | 7.02E-13 mmHg |
| Acidity (pKa) | pKa = 4.0 |
| Basicity (pKb) | 4.07 |
| Magnetic susceptibility (χ) | -9.7e-6 cm^3/mol |
| Refractive index (nD) | 1.520 |
| Dipole moment | 3.4739 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 230.6 J⋅mol⁻¹⋅K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -47.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -6873 kJ/mol |
| Pharmacology | |
| ATC code | A02BC01 |
| Hazards | |
| Main hazards | May cause eye irritation. |
| GHS labelling | GHS labelling: Not classified as hazardous according to GHS. |
| Pictograms | take with water", "do not chew", "take before meals", "do not crush", "swallow whole", "do not split |
| Signal word | No signal word |
| Hazard statements | No hazard statements. |
| Precautionary statements | Keep out of reach of children. If you are pregnant or breastfeeding, consult your doctor before use. Use only as directed. Do not use if allergic to omeprazole or any of the ingredients. Store in a cool, dry place away from direct sunlight. |
| NFPA 704 (fire diamond) | 0-1-0 |
| Flash point | > 188.5°C |
| Autoignition temperature | > 470°C |
| Lethal dose or concentration | LD50 (oral, rat): 2000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Omeprazole: "2,000 mg/kg (oral, rat) |
| NIOSH | MU7000000 |
| PEL (Permissible) | Not established. |
| REL (Recommended) | 20 mg once daily |
| IDLH (Immediate danger) | Not Listed |
| Related compounds | |
| Related compounds | Esomeprazole Lansoprazole Pantoprazole Rabeprazole Dexlansoprazole Timoprazole |
| Identification Parameter | Description & Commentary |
|---|---|
| Product Name | Omeprazole |
| IUPAC Name | 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole |
| Chemical Formula | C17H19N3O3S |
| Synonyms & Trade Names |
Synonyms in actual manufacturing contracts and batch records often include Losec, Prilosec, Antra, Mopral. Trade names are required for regulatory submissions; for active pharmaceutical ingredient (API) manufacturing, control of synonym assignment forms part of document traceability. |
| CAS Number | 73590-58-6 |
| HS Code & Customs Classification |
In standard production scale, Omeprazole for pharmaceutical use (API, not formulated) is commonly classified under HS Code 2933.99. Classification can depend on customer end-use (bulk API vs. finished formulations) and region-specific customs requirements. Regulatory teams reference HS codes directly in export documentation and customs declarations to minimize clearance delays and avoid reclassification risks. |
Consistency in product naming and traceability is critical. Minor variations in synonyms or trade names can cause complications during batch record review, especially when supplying regulated markets. The chemical formula and IUPAC name must correspond with all validated specifications; discrepancies during audit or regulatory inspection often prompt deviation investigations.
Raw material quality and source strongly affect batch-to-batch consistency, particularly for critical starting materials responsible for the methylsulfinyl-pyridine subunit. Process impurities, by-products, and isomer formation vary with route selection; for instance, choice of oxidant in the sulfoxidation stage impacts both the impurity profile and the downstream purification load. Assignment of the CAS number in all documentation ensures clear linkage between regulatory submissions and site output.
HS code accuracy is a key compliance requirement. Any difference between declared code and actual substance use may result in customs holds, retesting, or financial penalties. For omeprazole, customs classification must reflect intended use (API in bulk, finished dosage, or intermediates). Export and logistics teams update documentation and systems based on final product grading and destination.
Where product grade affects regulatory status, all product coding and identity sections in the database must reflect this status. Finished product traceability integrates these identifiers directly with the site ERP and quality management systems to promote reliable sourcing, facilitate investigations, and enable rapid response to product queries from regulatory bodies or customers.
Omeprazole in bulk manufacturing typically appears as a white to off-white crystalline powder. Color intensity depends on trace impurities and oxidative residues, which can arise when starting materials or reaction intermediates contain colored side products. Odor remains essentially non-existent in all grades designed for pharmaceutical formulation. Formulation-specific variations, such as micronized or granular grades, exhibit differences primarily in flow characteristics and compressibility—essential for tableting or encapsulation applications.
Melting point is routinely checked in quality control labs as an identity and purity check. Typical values are grade-dependent and influenced by residual solvents or polymorph form. Boiling point and flash point are rarely relevant in downstream handling; omeprazole is processed and handled in solid-state due to instability on heating and decomposition before boiling. Density data is critical only for volumetric packaging and blending processes; suppliers calibrate this property according to customer processing needs.
Omeprazole’s benzimidazole core is susceptible to degradation under acidic, humid, or strongly oxidative conditions. Product stability directly ties to packaging conditions, residual moisture, and oxygen levels during storage and shipping. Process batches exposed to ambient atmosphere during critical formulation steps present higher rates of impurity formation and require adjusted shelf life claims. Chemical reactivity is monitored at all stages—especially during granulation and film coating, where pH shifts and excipient compatibility may induce rapid decomposition.
Omeprazole remains practically insoluble in aqueous media across common pH ranges, demanding careful formulation for oral solid dosage forms. Solubility in organic solvents is grade-dependent; manufacturers tailor polymorph and particle size to suit suspension, enteric coating, or capsule content requirements. Solution preparation for analytical testing uses buffered or alkaline organic solutions to avoid degradation.
| Parameter | Pharmaceutical Grade | Custom Grade |
|---|---|---|
| Appearance | White to off-white powder | Granular, micronized, or as specified |
| Assay | Defined per pharmacopeial or customer standard | Specification per contract |
| Water Content | Specified by grade and region | On demand |
| Residue on Ignition | Controlled to meet pharmacopeial norms | Customizable |
| Heavy Metals | Pharmacopoeia or custom standard | Adjustable |
Impurity profiles vary with synthetic route, batch scale, and process controls. Monitoring of process and degradation impurities forms a core part of release testing. Chromatographic fingerprints differ based on raw material sources or catalyst selection. Acceptance criteria rely on internal experience and customer preference, especially with related compounds, isomeric residues, and trace byproducts.
Quality control applies validated analytical methods such as HPLC and GC in line with pharmacopeial or customer-mandated protocols. In-process checks focus on appearance, solubility, and intermediate purity, with method selection driven by batch size, regulatory region, and end-user requirements.
Primary raw materials include substituted pyridine and benzimidazole intermediates. Supply selection considers purity, impurity carryover, and trace element content. Sourcing arrangements adjust to global and local compliance regarding GMP or environmental criteria, with lot qualification integral for critical intermediates.
The established industrial route involves condensation between benzimidazole and pyridine derivatives in polar aprotic solvents using specific activating agents. Process chemistry may include catalytic coupling, protection-deprotection steps, and subsequent purification to remove structural analogues and residual metals. Preferred routes minimize hazardous reagents and waste, optimize yield, and provide easier purification at large scale.
Batch progress is tracked through sampling at critical synthesis and work-up steps. Control points include reaction temperature, pH, endpoint analysis of active content, and impurity tracking. Main purification stages utilize crystallization, filtration, and solvent exchange—with repeat recrystallizations applied for high-purity pharmaceutical batches. Air and moisture-sensitive process steps call for inert gas blanketing and controlled atmosphere work-ups.
Release testing combines physical inspection, chemical assay, impurity analysis, and dissolution studies. Control limits for each batch reflect process capability, starting material lot performance, and contract requirements. Deviations invoke root cause analysis with batch retention for trending and future investigation.
The benzimidazole scaffold provides points for further derivatization or salt formation. Suppliers evaluate side reaction chemistry to control for N-oxide or sulfoxide byproducts. Controlled modification under set catalytic or pH conditions generates various analogues for custom applications or further processing.
Key steps in Omeprazole synthesis demand precise control over temperature and pH, with common solvent use confined to polar aprotic or non-reactive organic phases. Catalytic hydrogenation or coupling may require inert or reduced pressure environments. Downstream reactions for analogues often substitute or protect various functional groups, requiring changes in catalyst type or process solvent.
Manufacturers can adapt the process to yield salts or custom polymorphs for regulatory or customer-driven purposes. By controlling conditions or introducing specific counterions, production enables supply of diverse forms needed for tailored release or bioavailability.
To extend shelf life, omeprazole must avoid high humidity, elevated temperature, and prolonged light exposure. Facilities deploy climate- and humidity-controlled areas to maintain batch stability. Nitrogen gas protection may supplement storage for high-purity grades or extended inventory hold periods. Sensitivity to oxidation and acid hydrolysis shapes local SOPs for internal logistics.
Container selection aligns with grade requirements. High-grade product typically fills in light-resistant, tight-seal packaging, with polymeric liners that minimize migration or adsorption. Compatibility checks prevent chemical interaction between packaging and the active substance—a key factor where long-term or large-batch storage is needed.
Shelf life depends on batch purity, upstream process history, and downstream handling. Degradation indicators include yellow to brown discoloration and formation of characteristic impurities profiled via HPLC. Shelf life claims follow empirical stability studies, typically tailored to storage regime and customer requirement.
Omeprazole classifies under GHS based on animal toxicity and irritation data; the precise classification shifts according to country-specific interpretation and grade contaminant levels. Handling risks arise mainly during bulk transfers, charging, and cleanup, where dust or direct skin contact can occur.
Appropriate risk phrases reflect manufacturing exposure points: prolonged inhalation of dust or spillage on skin during batch handling prompts use of local ventilation, full PPE, and dust control measures. Emergency protocols address accidental release, emphasizing avoidance of contact and proper containment and cleanup.
Manufacturer experience references available toxicity profiles, which support both occupational safety and end-use risk assessment. Repeated studies examine acute, sub-chronic, and chronic effects, with particular focus on respiratory sensitization, eye, and dermal effects for operational health management.
Plant practices govern internal exposure limits through engineering control, operational limits, and monitored personnel exposure. Variability depends on country regulations, batch scale, and frequency of open operation. Automated handling and closed system transfers address most points of dust and vapor exposure, with periodic review of workplace air for compliance and safety assurance.
Bulk omeprazole production runs continuously using established benzimidazole synthesis routes. Output volume is typically determined by reaction throughput, recovery efficiency, and isolation steps scheduled by batch size. Production output for pharmaceutical grade omeprazole correlates to reactor capacity, filtration efficiency, and downstream purification load. Supply remains steady, with short-term bottlenecks tied to solvent availability or maintenance of multi-step reactors. Priority allocations are sometimes required for GMP-compliant lots or special process grades. Output timeline depends on the complexity of customer specifications and QA release cycle.
Standard lead times reflect batch campaign schedules and routine analytical testing intervals. For most grades, shipment lead time begins after QA batch release and export documentation. Minimum order volume is set according to the lowest economically feasible batch size, which can differ by region, grade, or packaging choice. Custom lead times apply for project-specific specifications or requalification batches.
Packaging formats are defined by the downstream regulatory or manufacturing environment. Options include fiber drums with inner liners, antistatic bags, or specialized HDPE containers. Bulk filling and tamper-evident sealing practices depend on moisture sensitivity and trace contamination concerns. Pharmaceutical grade material is usually double-bagged or vacuum-sealed and nitrogen-purged by request to limit degradation during transit or extended storage.
Shipping practices account for temperature control, consignment security, and product traceability. Cold chain or ambient shipment is determined by stability data and route-specific risk assessment. Payment structures align with INCOTERM agreements, range from advance payment for new customers to net terms for established accounts, and integrate provisions for letters of credit on high-value consignments. Regulatory documentation, including CoAs, MSDS, and TSE/BSE-free declarations, accompany every shipment.
Raw material costs reflect the latest market dynamics affecting benzimidazole intermediates, sulfur chemistry auxiliaries, and solvents. Price sensitivity often traces to the purity of starting materials, process stream recovery, and cost of corrosion-resistant reactor components required for hazardous reagents. Input cost escalation may follow petrochemical feedstock fluctuations, currency exchange swings, and supply gaps for controlled intermediates.
Raw material price changes typically follow shifts in global supply contracts, regulatory tariffs, and changes in waste/recycling handling costs. Shortages of key precursors, such as methylating agents or fine chemical intermediates, push up finished goods cost. Environmental crackdowns can disrupt costs by forcing plant upgrades or temporary shutdowns. Labor cost and compliance with upgraded international GMP requirements impose additional variable costs, especially when new audit standards are implemented.
Pricing structure differentiates across grades based on release assay, purity profile, impurity spectrum, residual solvent levels, and documentation requirements. Pharmaceutical grade omeprazole commands a premium for full regulatory batch release, low heavy metals, and tight batch-to-batch impurity control. Technical grades for non-pharmaceutical applications have broader acceptance criteria, reflecting their downstream usage.
Bespoke packaging solutions for regulated markets, extended stability assurance, and full serialization escalate costs for higher value grades. Certification demands, such as GMP or CEP, and enhanced QC batch release protocols are major drivers of price differentials. For pharmaceutical use, the price increases with in-depth impurity profiling, validated stability studies, and supply chain auditability. Lower grades utilized in lab-scale or animal applications are generally offered at a baseline price reflecting lower compliance costs.
Global demand for omeprazole aligns with the widespread use in gastroenterology. Supply shows concentration in regions with established APIs manufacturing clusters, with China and India dominating raw material sourcing and volume output. EU and US customers typically insist on pedigree traceability, which requires segregated GMP lines and rigorous control, indirectly affecting global availability for those markets.
US and EU require complete compliance with ICH Q7 and pharmacopoeial monographs, which extend quality control timelines and increase auditing costs. In Japan, unique regulatory registration and re-testing add to lead time and cost structure. India and China operate with the largest installed capacity and focus on cost-efficient bulk production. Their supply chains rely on competitive logistical routes and access to local intermediates suppliers.
Medium-term forecasts factor in stable therapeutic demand but highlight volatility linked to raw material inputs, global regulatory crackdowns, and logistics uncertainties. As producers in China or India face tightening environmental controls, raw material input price movements could lift finished API costs. New trade regulations or export controls may cause tiered price jumps across regions. Higher regulatory costs in the US and EU amplify the price gap between strictly compliant and flexible supply chains. The price is expected to show modest upward drift barring large-scale innovation in process efficiency or raw material sourcing.
Market evaluation draws from internally tracked batch production costs, procurement contracts for intermediates, customer demand signals, and regulatory fee monitoring. Benchmarking uses data aggregated from published price indices, recent tenders from major healthcare buyers, and regular analysis of regulatory changes affecting process costs or batch release timing.
Ongoing consolidation in the global API sector has shifted price competition from finished goods to raw materials and compliance readiness. Some producers have migrated to green chemistry routes to reduce hazardous waste and lower variable costs in the long run.
Stricter EU and US scrutiny on NDMA and nitrosamine impurities compels upgrade of purification steps and enhanced QA analytical protocols. Requirements for extended batch traceability, environmental impact disclosure, and data integrity validation continue to be incorporated in global regulatory reviews.
Manufacturers have responded by retrofitting QA/QC labs, implementing secondary screening technologies for impurities, and engaging third-party auditors to manage evolving customer standards. Multi-site supply chain arrangements and early engagement with raw material vendors reduce exposure to single-point disruptions. Transparency on lead time risk, compliance status, and new certification processes prepares customers for regulator-driven changes in delivery timelines and product specification options.
Omeprazole, most commonly produced as a pharmaceutical intermediate, plays a direct role in manufacturing finished dosage forms for gastric acid suppression. Our production lines mainly support three market routes: bulk Active Pharmaceutical Ingredient (API) for tableting and encapsulation, pharmaceutical ingredient for compounding, and intermediate for custom synthesis. Veterinary markets and export-specific projects introduce further downstream customization needs.
Distributors and finished product manufacturers in different regions usually align their purchase strategy by the grade required for specific finished dosage forms, regulatory jurisdiction, and batch quantity. Segment-specific attention often centers on critical residual solvent profile, chiral purity, and stability under defined humidity and temperature conditions.
| Application | Grade | Key Parameters |
|---|---|---|
| Human Pharmaceuticals (oral solid dosage) | Pharma Grade (compendial: USP/EP/JP) | Assay, residual solvents, related substances, particle size, moisture content, identity |
| Pharmaceutical Intermediate (for downstream synthesis) | Technical/Industrial Grade | Process-dependent impurity profile, assay, solvent residues, stability |
| Veterinary Formulations | Veterinary/Feed Grade | Assay, defined residual solvent limits, contaminants per local pharmacopeia |
| Export Formulations (custom regulatory) | Custom/Regional Grade | Specification per destination requirements, documentation per region |
For solid dosage APIs, assay and related substances typically require tight control as finished formulations directly rely on input quality for therapeutic index. Moisture content and particle size distribution affect blending, compression, and dissolution properties.
Technical grades function as intermediates where some parameters—like minor solvent residues—are less stringent, but downstream users may impose proprietary purifications. Veterinary and export grades align with differing regional guidelines; here, contaminant screening may vary and shelf life claims often adjust by moisture barrier packaging and final handling.
Identify the end-use: finished oral pharmaceuticals, veterinary medicine, intermediate for in-house synthesis, or export to a jurisdiction with unique compendial authority. The rationale for application sharply guides grade selection and final QC acceptance criteria.
Based on market—domestic or international—gather the latest pharmacopeial (USP, EP, JP, or local) and documentation requirements. Verify certificate of suitability or DMF availability if required by your regulatory strategy.
Define assay limits and quantify impurities such as enantiomeric excess, process-sourced byproducts, heavy metals, and solvent residues. High-purity API grades call for investment in advanced purification and analytical methodology. Technical and intermediate grades allow for adapted purification and simplified batch analytics, pending end-use.
API projects with high annualized requirements typically benefit from custom batch reservation and direct supply contracts for cost management. Low-volume or development projects may lean on multi-purpose batch allocation with flexible lot release criteria.
As part of finalizing the supply chain, request samples and batch documentation for your intended application. In-process validation, pilot formulation, and comparative release tests can confirm that grade, physical characteristics, and impurity profile align with your registered specifications or production process needs.
Key starting materials, solvents, and reagents are sourced to ensure minimal carryover impurities, especially halogenated precursors. Trace residues from critical reagents such as alkyl halides carry forward through downstream processing if not adequately purged at intermediate isolation or recrystallization stages.
Production follows multi-step synthesis, where process route (ethyl vs. methyl ester pathway; solvent system selection) determines selectivity, impurity load, and feasibility of purification. Choice of route reflects regulatory acceptance and plant capability for specific cleaning validation, exception handling, and waste treatment.
Tight operation control occurs at stages susceptible to chiral inversion and residual solvent breakthrough. Intermediate isolation, controlled crystallization, and real-time monitoring of critical quality attributes (CQA) prevent out-of-spec product release.
Residual process reagents, byproducts, and degradation by light, heat, or moisture require targeted monitoring, especially before final isolation and drying phases. Grade specification determines how strictly controlled these are; API grade receives highest scrutiny.
Grade-specific purification includes crystallization, extraction, and sometimes column chromatography. For regulated APIs, multi-level purification targets both total impurity reduction and specific byproduct elimination. Environmental controls during finishing prevent batch-to-batch cross-contamination.
Regular in-process checks at each stage confirm target reaction completion, reject off-spec intermediates, and steer batch adjustments. Controls extend to solvent levels, solid phase characteristics, and pre-final drying checks adapted by product grade and final application.
Consistent quality relies on validated control plans tied to equipment cleaning, raw material intake, and operator oversight. Pharma and export grades impose more frequent batch monitoring and lot traceability; technical grades use representative sampling based on historical run data.
Final lots pass release based on both internal plant criteria and mutually agreed customer specifications. Tightest release margins are set for human pharmaceutical applications, including full impurity profile, residual solvent certificates, and stability data under defined storage conditions.
Quality control managers at our manufacturing site require certification according to internationally recognized standards to ensure process control and traceability. Certification such as ISO 9001 covers quality system architecture, recordkeeping, and corrective action guidelines. Regulatory audits from authorities—depending on export country—determine site suitability for API and pharmaceutical intermediate production. Our facility’s manufacturing records, deviation logs, and batch release procedures reflect regulatory and customer requirements. Long-term production partners typically review audit histories and corrective action logs before approving site supply.
Omeprazole destined for regulated markets can be produced under Good Manufacturing Practice (GMP) conditions, evidenced by site-specific documentation, inspection outcomes, and client audit accessibility. Product-specific certifications and regulatory filings, such as DMF submission or CEP approval, apply to selected grades and are disclosed only after execution of non-disclosure agreements and customer request alignment. Not all Omeprazole grades qualify for regulated applications—some batches are tailored for less-regulated or technical markets, with technical validation differing from that required for pharmaceutical grades. Data packages and regulatory filings remain specific to batch, production route, and origin.
Manufacturers maintain batch-specific documentation: certificate of analysis, analytical method validation data, impurity profile history, and material origin traceability. Consistent batch release relies on defined internal acceptance criteria, based on product grade and end-use. Ongoing process validation studies monitor batch repeatability and impurity trends. Retained sample registration and complaint traceability fulfill both internal and customer audit needs. Quality control teams update documentation in response to changes in raw materials or regulatory expectations—customers may request additional data packages relevant to their own compliance requirements. Complete details on heavy metal content, microbial limits, or residual solvents are provided in grade-, batch-, or region-specific reports.
Consistent Omeprazole supply arises from annual demand forecasting and production slot reservation. Customers submitting volume projections in advance receive preferential scheduling. Our supply chain team tracks input availability from key raw materials, builds safety stock for prioritized accounts, and adjusts output to balance multi-customer portfolios. Unplanned demand spikes are managed using finished goods and intermediate reserves. Customers can engage through volume contracts, spot orders, or rolling forecasts—each mode affects production scheduling flexibility and price negotiation bandwidth.
Manufacturing facilities equipped with core reactor trains and dedicated lines for sensitive APIs control contamination risk and batch variability. Process engineers oversee step-specific controls, especially during key intermediate coupling and chiral resolution phases where minor deviations introduce off-spec profiles. Capacity constraints evolve based on client qualification cycle, regulatory approval timeline, and module expansion plans. Supply capability per order is grade-, validation-, and route-dependent, requiring production teams to continuously monitor output versus installed capacity, campaign purity, and downline release clearance.
Requests for Omeprazole samples must specify intended use, grade, regulatory status, and volume required. Technical teams coordinate with clients to clarify specification alignment and release criteria before dispatching controlled quantities, often governed by material transfer agreements. Quality control provides corresponding analytical data packs linked to each sample lot, including impurity and residual solvent profiles, as recorded in main batch documents. Feedback loops operate between technical support and customer QA for assessment and optimization, ensuring transparency in process capability and batch-to-batch reproducibility.
Clients choosing flexible procurement may select from several options: minimum order batch production, campaign manufacturing for multi-month needs, or make-to-order protocols requiring rolling forecasts. Cost and lead-time projections are calculated based on raw material volatility, campaign size, and production route. Technical account managers provide risk evaluations for procurement methods, such as buffer stock arrangements, consignment programs, or forward order bookings. Each cooperation mode requires early forecast submissions, clear quality spec alignment, and mutually agreed investigation protocols for deviations or complaint handling to ensure continuity and supply confidence.
Process route innovation is a central concern for Omeprazole manufacturing. Teams focus on optimizing synthesis to minimize secondary impurities and maximize conversion rates, especially under regulatory pressure for lower impurity thresholds. Analysts keep a close watch on cost structures, as raw material fluctuation and process yield directly drive commercial competitiveness. Key process parameters, such as solvent selection and crystallization control, receive routine scrutiny to limit the formation of sulfone and related degradation products. Customizing process for solid-state properties, including polymorph stability and particle size control, emerges as a priority for oral formulation partners.
Demand grows for Omeprazole suitable for multi-particulate and immediate-release systems. R&D activity now investigates suitability for orally disintegrating delivery and pediatric suspensions, with application-specific granule engineering directly affecting release profiles and excipient compatibility. Veterinary product lines request adaptation in granule morphology and impurity specification, where stability across feed and water-soluble forms becomes pivotal.
Main challenges involve precise control of process impurities and by-products generated from oxidation and incomplete methylation steps. Robust risk management targets dimensional control over API crystallinity to address downstream tableting and dissolution variability. Development teams have achieved incremental enhancements in purification steps, introducing more effective adsorption and filtration strategies. Stability enhancement remains an ongoing concern for bulk product intended for long shelf-life formulations or hot-climate export.
Based on observed prescription trends and growing demand in emerging markets, global bulk requirement for Omeprazole is set for stable, moderate growth, barring sudden changes in generics legislation or competitive launches. Demand shifts seasonally and sometimes regionally based on public health and reimbursement conditions. Extended markets such as combination therapies and pediatric adaptions add complexity to grade and specification requirements in forward planning.
Manufacturing lines are moving toward continuous processing to improve batch consistency and reduce scale-up risk for regulatory compliance. Analytical characterization advances, especially in LC-MS and solid-state NMR, enhance the ability to identify and control trace-level impurities. Inline monitoring and real-time release testing incrementally replace former offline batch release protocols, supporting faster release cycles for contract partners.
Attention intensifies on solvent recovery systems and reduction of chlorinated wastes inherent to some process routes. Manufacturers work on adopting greener solvents and catalytic systems as feasible while maintaining required product purity. Supply chain teams evaluate renewable sourcing of primary raw materials and emphasize effective waste minimization strategies in both pilot and commercial scale, as environmental permits grow more demanding. Residual solvent control remains a focal in both worker safety management and downstream product acceptance.
Each technical inquiry receives support from senior chemists familiar with current production batches and analytical results. Project-specific consultation includes discussion of process history, impurity profile evolution, and the impact of raw material variation on the final release. Customers seeking specialized grades or non-standard specifications receive direct access to formulation and process engineering teams.
Support extends into customer tableting trials and stability protocol design for all Omeprazole grades. Teams provide guidance on re-dispersion, pre-milling adjustments, and compatibility with selected excipients during pilot scale-up. Troubleshooting involves detailed batch history access, root cause analysis of out-of-spec observations, and, where relevant, targeted process re-optimization advice aligned with customer feedback.
Ongoing batch tracking, temperature excursion management, and quality documentation updates form the backbone of after-sales service. In the event of specification drift or unforeseen performance issues, remediation involves coordinated technical review and, when necessary, retesting or batch replacement per agreed conditions. Customer audits receive full traceability response, including release standards and batch-specific analytical profiles upon request. Ongoing regulatory updates or specification revisions are shared proactively.
Producing Omeprazole at scale demands more than access to raw materials and chemical reactors. Process steps require close supervision from active ingredient synthesis right through to finished product packaging. Each batch follows a defined operational protocol, with real-time monitoring of critical parameters such as pH, temperature, solvent recovery, and particle profile. Our teams run multiple reactors and isolation systems configured for bulk active pharmaceutical ingredient (API) production. Routine in-process testing, high-performance liquid chromatography, and impurity profiling maintain batch traceability and support regulatory audits.
Omeprazole functions primarily as a proton pump inhibitor for pharmaceutical products. Bulk buyers leverage Omeprazole for the manufacture of gastro-resistant tablets, capsules, and powder blends. Custom processing lines incorporate the API into complex formulations for domestic and export markets. Contract manufacturers rely on consistent product quality for each downstream processing step, especially during granulation, coating, and final packaging. Besides finished dosage forms, Omeprazole also serves as a reference product in formulation development and process validation labs.
Our facility applies validated analytical methods for each production lot. Quality checks encompass visual inspection, loss on drying, heavy metal content, and residual solvent levels. Every sample undergoes rigorous identity confirmation and related substance testing to guarantee compliance with major pharmacopeial standards. Data integrity systems ensure traceable results for physical, chemical, and microbiological assays. Process deviations trigger a root-cause analysis and batch segregation, minimizing the risk of non-conforming shipments.
To safeguard product against moisture, light, and contaminants, Omeprazole ships in sealed, double-lined polyethylene bags placed inside fiber drums. All packaging options comply with bulk transport needs and meet regulatory requirements for pharmaceutical API logistics. Our onsite warehousing supports regular and scheduled deliveries, covering both bulk and smaller, customized orders. Documentation accompanies each shipment, reflecting actual test results, batch identity, and chain-of-custody records from packing to handoff.
Our technical advisors and process engineers assist customers with integration requirements, from API compatibility assessments to optimizing blending and storage conditions. Whether addressing formulation questions or assisting with analytical validation, direct access to production experts streamlines technical problem-solving. Regular technical updates and change notifications equip buyers to manage their own compliance and keep pace with process changes relevant to their own quality systems.
Sourcing Omeprazole directly from production ensures predictable supply and proprietary access to the manufacturing process. Manufacturers and procurement teams benefit from batch-level traceability and rapid response to documentation requests. Distributors gain confidence in market commitments through scheduled supply planning and full transparency over capacity and lead times. Aligning with a direct manufacturer controls exposure to supply chain uncertainties and aligns production schedules with market demand cycles.
| Feature | Benefit |
|---|---|
| Continuous In-House Production | Stable availability and immediate access to next-batch material |
| Batched Quality Control | Full traceability and compliance with major pharmacopeias |
| Pharmaceutical Packaging | Reduces risk of contamination and supports global transit |
| Technical Customer Portal | Direct troubleshooting and support for complex industrial applications |
| Onsite Inventory | Supports high-volume and just-in-time delivery arrangements |
We have produced Omeprazole bulk powder in our facilities for years. In essence, Omeprazole operates as a proton pump inhibitor. The science is straightforward: this compound blocks the H+/K+-ATPase enzyme in the stomach’s parietal cells. This enzyme, often referred to as the gastric proton pump, drives the secretion of gastric acid. By stopping the pump’s function, omeprazole sharply cuts down acid levels in the stomach. That mechanism has proven critical for treating acid-related disorders like reflux, ulcers, and Zollinger-Ellison syndrome.
Through our in-house testing, we have found the compound’s activity relies on an exact enteric formulation. Stomach acid breaks down plain omeprazole readily, so for drug producers using our bulk powder, proper tablet or capsule protection is vital. Only then does the drug pass unchanged through the stomach, reach the small intestine, absorb into the bloodstream, and proceed to inactivate the proton pumps.
From a production standpoint, Omeprazole bulk powder brings some handling challenges. Unlike stable excipients or buffers, omeprazole degrades quickly in moisture and under acidic or basic conditions. Our technical team recommends storage below 25°C. We utilize low-permeability, triple-laminated packaging to shut out humidity and oxygen, both key threats to shelf life. Open storage or careless repackaging can lead to significant potency loss long before a final dosage form reaches the pharmacy.
Based on our analysis, protect Omeprazole from both light and air exposure. This is not just a guideline—our stability data has shown visible decomposition under fluorescent lights or on exposure to ambient air for extended periods. In our plant, we run all filling, sampling, and quality steps under controlled atmospheres. Every drum receives a tamper-evident closure plus an inner liner to block ingress.
Every batch we release leaves the factory vacuum-sealed and inert-gassed to lock out the ambient environment. If you must subdivide or repackage, move fast and seal tightly—omitting this step leads to hydrolysis or oxidation, two main routes of breakdown. From our records, temperature excursions above recommended levels correlate with accelerated color change and assay drop.
In our workflow, powder handling always takes place in low-humidity rooms, with continuous monitoring. Even brief exposure at a relative humidity above 60% spikes the risk of degradation. We also mobilize desiccant packs in all transit containers for deliveries lasting longer than two days.
We invest in stability studies that drive our recommendations, not broad warnings. Clients ask us why we stress such detail in handling and storage. The answer comes from years observing how minor lapses can trigger substantial product loss. As manufacturers, we see it as our duty to provide both the product and the practical, field-tested know-how that keeps omeprazole stable from our production line to yours.
Direct feedback from pharmaceutical partners using our powder continually shapes our process controls. Our attention to moisture and oxygen control doesn’t just protect physical inventory—it safeguards patient outcomes by helping ensure the active stays potent at every point in the distribution chain.
Every industrial producer of active pharmaceutical ingredients faces the same balancing act: maintain a robust supply chain while responding to evolving customer demand and regulatory expectations. As a direct manufacturer of Omeprazole, we’ve spent decades refining our practices, not only to stay competitive but to provide reliable and predictable service to our buyers around the world.
Manufacturing Omeprazole at scale involves much more than setting up a reactor and waiting for the product to roll off the line. Our facilities run 24 hours a day, leveraging automated systems and rigorous quality controls. The cost structure for producing Omeprazole divides into raw materials, labor, utilities, cleaning validation between batches, and extensive analytical testing. Small production runs disrupt workflow and significantly raise unit costs. As a result, we set minimum order quantities that reflect economic batch sizes. These floor quantities keep production lines efficient and ensure customer pricing stays competitive. When we set a threshold, it removes unnecessary bottlenecks—no equipment tied up for small runs, no excess downtime, and reduced risk of cross-contamination during changeovers.
To illustrate: batch reactors designed for several hundred kilos do not shut down and retool for small-lot production. Tablets or capsule manufacturers further downstream can count on our consistent minimum lot sizes to plan their own output and manage supply chain costs. Our standard minimum order quantity for Omeprazole API in most regional markets sits at the kilo- or multi-kilo level, depending on regulatory controls and registered customer demand.
Lead times for Omeprazole depend on actual plant schedules and raw material availability. Regulatory compliance and validated cleaning cycles add further complexity, all of which require tight upstream planning. Omeprazole synthesis involves multiple steps, including chromatographic purification and controlled crystallization. Any deviation from validated protocols triggers extended testing and investigation, which directly impacts availability. Our plant operates on a continuous scheduling cycle, and lead times for new orders typically range from a few weeks to two months, subject to capacity. A large demand spike or a need for a new regulatory submission can shift these timelines, which is why our account managers work daily with operations and QA to keep customers informed of timing before formal scheduling begins.
Our logistics team coordinates directly with major port and freight operators. Finished API batches are released only after all quality results are reviewed and approved, ensuring shipments meet European, US, or regional pharmacopoeia standards. Documentation travels with the consignment, so buyers can import and release product without procedural delay. We do not bulk hold finished Omeprazole for speculative sale—every batch is tied to production schedules confirmed with real purchase orders.
Real-world experience tells us that transparency and regular communication minimize delivery uncertainty. Buyers working within established frameworks—for example, annual contracts outlining forecasted volume—see the shortest lead times and best pricing, because we can optimize production runs and raw material contracts. Smaller buyers or those requesting non-standard packaging should prepare for longer timelines, as customization extends both production and QA processes. By aligning expectations early and providing accurate forecasts, our partners mitigate their own supply chain risk and avoid product shortages in a volatile pharmaceutical environment.
Our factory’s philosophy stays simple: set responsible minimum order quantities rooted in validated process economics, commit to clear lead times, and work directly with customers to solve logistical hurdles. That’s the foundation of a credible manufacturer—one that stands behind every shipment of Omeprazole delivered.
Manufacturing omeprazole is highly technical, but what happens after it leaves the production site matters just as much. From the production line to clients’ shelves, each batch follows strict GDP and GMP measures to maintain identity, quality, and safety. Many ask if omeprazole “complies” in transport and storage — this is not a box we check once and ignore; it guides every batch that leaves our facility and is the reason we document each detail.
Omeprazole’s sensitivity to light, moisture, and temperature challenges any logistics network. Our quality assurance staff performs risk assessments before each shipment, evaluating routes and climate influences. For temperature, shipment policies require the use of qualified insulated packaging in non-refrigerated scenarios to keep conditions below thresholds (often 25°C unless otherwise specified per territory regulations). Temperature and humidity loggers record environmental conditions during each shipment, and our technical team reviews these logs upon delivery and receives automatic alerts in case of excursions beyond critical limits.
To comply with GDP, only GDP-audited carriers handle our transportation. Training extends to warehouse and local distribution staff. All handling personnel follow procedures for rapid offloading and secure palletization to restrict exposure to outdoors and accidental damage. Each container’s security seal has a unique code, and we keep a scan record linked to production and delivery documentation. Deviations prompt an investigation and hold on any affected inventory—release happens only after documented QA review.
We maintain traceability starting from our raw materials right through to client delivery. Digital batch records serve internal and regulatory needs, matching every shipment to production data and quality test results. For every delivery of omeprazole, a Certificate of Analysis detailing both identity and purity accompanies the shipment. Extended documentation, including transport temperature monitoring data and compliance statements, is available for audit at any time. Clients requesting specific GDP or GMP certificates for a particular region (EU, Middle East, Asia-Pacific) can receive full audit-trace documentation from our compliance office.
Unplanned delays at customs and border crossings remain a challenge worldwide. To manage, we prepare secondary insulated shrouds and temperature-stable pallets for shipments likely to wait extended periods on docks. In proven high-risk routes, we work with carriers deploying real-time GPS and temperature monitoring. Communications are streamlined between our shipping manager and the importer’s QA representative—shipment reports and temperature data arrive before the physical goods, so they can coordinate local handling in advance.
Omeprazole’s sensitivity also applies during storage at client warehouses. Bulk and repackaged goods should not experience sunlight, damp, or excessive heat, even for short periods. Our technical support frequently shares best-practice SOPs with partners, offering training updates if there are regulatory changes or audit findings in their protocols. The compliance process runs both ways—feedback from client audits informs our process upgrades, keeping our methods aligned with evolving GDP and GMP requirements.
Compliance with GDP and GMP never stands still. Our internal audits include end-to-end reviews of specific omeprazole shipments selected at random. Findings go to our compliance managers, who update policies and conduct refresher training for all staff involved. Customers benefit directly from this process: lower risk, better predictability, and full traceability—from our factory to their warehouse shelf. In this industry, reputation depends on daily diligence; documentation proves it, and continuous improvement makes it real.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
